OPKO Health (NASDAQ:OPK) Coverage Initiated at JPMorgan Chase & Co.

JPMorgan Chase & Co. began coverage on shares of OPKO Health (NASDAQ:OPK) in a research report sent to investors on Friday, MarketBeat Ratings reports. The firm issued a neutral rating on the biotechnology company’s stock.

Several other brokerages have also commented on OPK. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Monday, April 7th. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research report on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, OPKO Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $2.75.

OPKO Health Stock Down 3.4 %

OPKO Health stock opened at $1.41 on Friday. The stock’s 50 day moving average price is $1.64 and its 200 day moving average price is $1.57. The company has a market cap of $946.89 million, a PE ratio of -7.42 and a beta of 1.78. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health has a 1-year low of $1.15 and a 1-year high of $2.04.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million for the quarter, compared to analysts’ expectations of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. On average, sell-side analysts predict that OPKO Health will post -0.25 EPS for the current fiscal year.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 125,000 shares of the business’s stock in a transaction on Thursday, April 10th. The stock was bought at an average cost of $1.36 per share, for a total transaction of $170,000.00. Following the acquisition, the chief executive officer now owns 214,001,448 shares of the company’s stock, valued at approximately $291,041,969.28. The trade was a 0.06 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders purchased a total of 814,971 shares of company stock valued at $1,308,192 over the last three months. 49.69% of the stock is currently owned by insiders.

Institutional Investors Weigh In On OPKO Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC boosted its stake in OPKO Health by 75.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after buying an additional 12,417 shares during the last quarter. Pallas Capital Advisors LLC acquired a new position in shares of OPKO Health in the 1st quarter valued at $43,000. Cibc World Markets Corp acquired a new position in OPKO Health in the fourth quarter valued at $45,000. Zacks Investment Management purchased a new stake in OPKO Health during the fourth quarter valued at about $49,000. Finally, Ieq Capital LLC purchased a new stake in OPKO Health during the fourth quarter valued at about $52,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.